Karin Söderkvist
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karin Söderkvist has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Björn Zackrisson
Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden
7 shared publications - Tufve Nyholm
Umeå University
5 shared publications Anders Ullén
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
4 shared publications- Fredrik Liedberg
Department of Translational Medicine Lund University Malmö Sweden
4 shared publications - Per Nilsson
Department of Clinical Sciences (Lund), Lund University, Lund, Sweden; Department of Hematology, Oncology & Radiation Physics, Skåne University Hospital, Lund, Sweden
4 shared publications - Truls Gårdmark
Department of Clinical Sciences, Danderyd Hospital Karolinska Institute Stockholm Sweden
4 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in BJU International
Fracture risk and initiation of bone‐specific drug therapy following radical cystectomy with urinary diversion
Objectives: To assess the risk of fractures among patients with bladder cancer who underwent radical cystectomy (RC) with urinary diversion (UD), compared with matched referents from the general population. Patients/Subjects and Methods: We identified 2908 patients who underwent RC between 2011 and 2019, and 13 669 matched referents in a nationwide, register‐based Swedish cohort study. Outcomes were femoral fracture, any fracture, and initiation of bone‐specific drug therapy (BDT). Cumulative incidence was estimated using competing‐risk analyses, and hazard ratios (HRs) were derived from multivariable Cox models stratified by sex. Additional analyses were conducted among patients with muscle‐invasive bladder cancer treated with curative radiotherapy ( n = 328). Results: Compared to referents, RC with UD was associated with a higher cumulative incidence of fractures. Women had an increased risk of femoral fracture (HR 1.97, 95% confidence interval [CI] 1.25–3.10) and any fracture (HR 2.06, 95% CI 1.54–2.76), while men had an increased risk of any fracture (HR 1.51, 95% CI 1.22–1.88). No association was observed for initiation of BDT in either sex. In the additional cohort, men treated with radiotherapy had an increased risk of any fracture (HR 2.14, 95% CI 1.26–3.62), whereas estimates for women were imprecise. Conclusion: Patients undergoing RC with UD experienced increased fracture risks, particularly women. Additional analyses suggest that fracture risk may be influenced by factors related to both bladder cancer and its treatment, although the strongest and most consistent associations were observed following RC with UD. These findings support increased attention to bone health in these patients.
- 8 October 2026
- Published by Wiley in BJU International
Open AccessFracture risk and initiation of bone‐specific drug therapy following radical cystectomy with urinary diversion
Objectives: To assess the risk of fractures among patients with bladder cancer who underwent radical cystectomy (RC) with urinary diversion (UD), compared with matched referents from the general population. Patients/Subjects and Methods: We identified 2908 patients who underwent RC between 2011 and 2019, and 13 669 matched referents in a nationwide, register‐based Swedish cohort study. Outcomes were femoral fracture, any fracture, and initiation of bone‐specific drug therapy (BDT). Cumulative incidence was estimated using competing‐risk analyses, and hazard ratios (HRs) were derived from multivariable Cox models stratified by sex. Additional analyses were conducted among patients with muscle‐invasive bladder cancer treated with curative radiotherapy ( n = 328). Results: Compared to referents, RC with UD was associated with a higher cumulative incidence of fractures. Women had an increased risk of femoral fracture (HR 1.97, 95% confidence interval [CI] 1.25–3.10) and any fracture (HR 2.06, 95% CI 1.54–2.76), while men had an increased risk of any fracture (HR 1.51, 95% CI 1.22–1.88). No association was observed for initiation of BDT in either sex. In the additional cohort, men treated with radiotherapy had an increased risk of any fracture (HR 2.14, 95% CI 1.26–3.62), whereas estimates for women were imprecise. Conclusion: Patients undergoing RC with UD experienced increased fracture risks, particularly women. Additional analyses suggest that fracture risk may be influenced by factors related to both bladder cancer and its treatment, although the strongest and most consistent associations were observed following RC with UD. These findings support increased attention to bone health in these patients.
- Open Access
- 23 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101175
Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial
- 23 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101175
Open AccessOutcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial
- Open Access
- 7 April 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 38
Automatic segmentation of the urethra and prostate zones with deep learning on T2-weighted magnetic resonance imaging
- 7 April 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 38
Open AccessAutomatic segmentation of the urethra and prostate zones with deep learning on T2-weighted magnetic resonance imaging
- Open Access
- 27 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1482-1488
Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference
Background and purpose: The study aims to evaluate dosimetric properties of hypofractionated treatment plans integrating focal boost, using registered whole-mount histopathology (WMHP) as reference standard. Methods: Fifteen men from the PAMP trial (EudraCT: 2015-005046-55) were included. Participants had ≥ 1 ISUP Grade group ≥ 4 lesion and underwent [68Ga]prostate-specific membrane antigen (PSMA) positron emission tomography/multiparametric magnetic resonance imaging (PET/mpMRI) and [11C]Acetate-PET/computed tomography before radical prostatectomy. Four radiation oncologists delineated gross tumor volumes (GTVs) on PSMA-PET/mpMRI. Sixty treatment plans were optimized, one per GTV and patient. Prostate planning target volumes were prescribed 42.7 Gy in seven fractions, with a simultaneous GTV boost up to 49.0 Gy, prioritizing organs at risk (OARs). Digital WMHP provided Gleason grading and was co-registered with in-vivo imaging. Target coverage for GTVs and voxels sharing Gleason patterns (GPs) was assessed via dose-volume histogram (DVH) analysis. Interobserver agreement in GTV-delineations was quantified with Fleiss’ kappa. Results: The median GTV dose per plan (D50) ranged from 48.3 to 49.1 Gy. For voxels with the highest GP, D50 was 42.9–49.2 Gy, exceeding 47.2 Gy in all except one plan. In lowest pattern voxels, D50 was 42.5–49.3 Gy, and below 43.4 Gy in over half the plans. Significant positive correlations between Fleiss’ kappa and DVH parameters appeared only for GP 5 regions, specifically for Fleiss’ kappa and D50 for two observers and the average D50 across observers. Interpretation: The histologically confirmed tumor was only partially boosted. Regions with more aggressive disease received better coverage. These findings provide a rational for prioritizing OARs in treatment planning.
- 27 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1482-1488
Open AccessUltra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference
Background and purpose: The study aims to evaluate dosimetric properties of hypofractionated treatment plans integrating focal boost, using registered whole-mount histopathology (WMHP) as reference standard. Methods: Fifteen men from the PAMP trial (EudraCT: 2015-005046-55) were included. Participants had ≥ 1 ISUP Grade group ≥ 4 lesion and underwent [68Ga]prostate-specific membrane antigen (PSMA) positron emission tomography/multiparametric magnetic resonance imaging (PET/mpMRI) and [11C]Acetate-PET/computed tomography before radical prostatectomy. Four radiation oncologists delineated gross tumor volumes (GTVs) on PSMA-PET/mpMRI. Sixty treatment plans were optimized, one per GTV and patient. Prostate planning target volumes were prescribed 42.7 Gy in seven fractions, with a simultaneous GTV boost up to 49.0 Gy, prioritizing organs at risk (OARs). Digital WMHP provided Gleason grading and was co-registered with in-vivo imaging. Target coverage for GTVs and voxels sharing Gleason patterns (GPs) was assessed via dose-volume histogram (DVH) analysis. Interobserver agreement in GTV-delineations was quantified with Fleiss’ kappa. Results: The median GTV dose per plan (D50) ranged from 48.3 to 49.1 Gy. For voxels with the highest GP, D50 was 42.9–49.2 Gy, exceeding 47.2 Gy in all except one plan. In lowest pattern voxels, D50 was 42.5–49.3 Gy, and below 43.4 Gy in over half the plans. Significant positive correlations between Fleiss’ kappa and DVH parameters appeared only for GP 5 regions, specifically for Fleiss’ kappa and D50 for two observers and the average D50 across observers. Interpretation: The histologically confirmed tumor was only partially boosted. Regions with more aggressive disease received better coverage. These findings provide a rational for prioritizing OARs in treatment planning.
- Open Access
- 22 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9)
Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas
Objectives: To investigate the association between waiting time and outcomes in patients with upper tract urothelial carcinomas (UTUC).Patients and methods: We studied a population‐based cohort of 858 patients in BladderBaSe 2.0 subjected to extirpative surgery for UTUC 2015–2019 in Sweden. Diagnostic waiting time (from referral to diagnosis, reference <1 week), treatment waiting time (from diagnosis to surgery, reference <5 weeks) and total waiting time (reference 4 weeks was associated with stage progression (OR 2.44 [95% CI 1.00–5.95]), and in patients with UTUC in the ureter, a treatment waiting time between 5 and 10 weeks was associated to worse DSS (HR 2.85 (95% CI 1.03–7.89).Conclusions: In general, shorter care pathways were linked to beneficial survival estimates, yet some estimates may be influenced by selection bias due to prioritizing short waiting times for patients with advanced and/or overt symptomatic tumours. Stage progression with increased waiting time may indicate an underlying causal mechanism.
- 22 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9)
Open AccessWaiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas
Objectives: To investigate the association between waiting time and outcomes in patients with upper tract urothelial carcinomas (UTUC).Patients and methods: We studied a population‐based cohort of 858 patients in BladderBaSe 2.0 subjected to extirpative surgery for UTUC 2015–2019 in Sweden. Diagnostic waiting time (from referral to diagnosis, reference <1 week), treatment waiting time (from diagnosis to surgery, reference <5 weeks) and total waiting time (reference 4 weeks was associated with stage progression (OR 2.44 [95% CI 1.00–5.95]), and in patients with UTUC in the ureter, a treatment waiting time between 5 and 10 weeks was associated to worse DSS (HR 2.85 (95% CI 1.03–7.89).Conclusions: In general, shorter care pathways were linked to beneficial survival estimates, yet some estimates may be influenced by selection bias due to prioritizing short waiting times for patients with advanced and/or overt symptomatic tumours. Stage progression with increased waiting time may indicate an underlying causal mechanism.
- Open Access
- 23 August 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 31, 100633
Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging
- 23 August 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 31, 100633
Open AccessHistopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging
- Open Access
- 16 January 2024
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 59, 19-25
Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey
Objective: To report national data on diagnostics and treatment of upper tract urothelial carcinoma (UTUC) from the Swedish National Registry of Urinary Bladder Cancer (SNRUBC). Patients and methods: Data from 2015 to 2021 were retrieved, and descriptive analyses were performed regarding incidence, diagnostic modalities, preoperative tumor staging, quality indicators for treatment including the use of standardized care pathways (SCP) and multidisciplinary tumor boards (MDTB). Time trends were explored for the study period. Results: Registrations included 1,213 patients with renal pelvic cancer and 911 patients with ureteric cancer with a median age of 74 (interquartile range [IQR] 70–77) and 75 (IQR 71–78) years, respectively. Incidence rates of UTUC were stable, as were proportions of curative treatment intent. Median number of days from referral to treatment was 76 (IQR 57–99) and 90 (IQR 72–118) days, respectively, for tumors of the renal pelvis and ureter, which remained unchanged after introduction of SCP in 2016. Noticeable trends included stable use of kidney-sparing surgery and increased use of MDTB. For radical nephroureterectomy (RNU), robot-assisted technique usage increased even for non-organ-confined tumors (cT3-4) and in one out of three patients undergoing RNU a bladder cuff excision was not registered. Conclusions: The population-based SNRUBC with high coverage contributes to the knowledge about UTUC with granular and generalizable data. The present study reveals a high proportion of patients not subjected to curatively intended treatment and suggests unmet needs to shorten lead times to treatment and use of bladder cuff excision when performing radical surgery for UTUC in Sweden.
- 16 January 2024
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 59, 19-25
Open AccessDiagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey
Objective: To report national data on diagnostics and treatment of upper tract urothelial carcinoma (UTUC) from the Swedish National Registry of Urinary Bladder Cancer (SNRUBC). Patients and methods: Data from 2015 to 2021 were retrieved, and descriptive analyses were performed regarding incidence, diagnostic modalities, preoperative tumor staging, quality indicators for treatment including the use of standardized care pathways (SCP) and multidisciplinary tumor boards (MDTB). Time trends were explored for the study period. Results: Registrations included 1,213 patients with renal pelvic cancer and 911 patients with ureteric cancer with a median age of 74 (interquartile range [IQR] 70–77) and 75 (IQR 71–78) years, respectively. Incidence rates of UTUC were stable, as were proportions of curative treatment intent. Median number of days from referral to treatment was 76 (IQR 57–99) and 90 (IQR 72–118) days, respectively, for tumors of the renal pelvis and ureter, which remained unchanged after introduction of SCP in 2016. Noticeable trends included stable use of kidney-sparing surgery and increased use of MDTB. For radical nephroureterectomy (RNU), robot-assisted technique usage increased even for non-organ-confined tumors (cT3-4) and in one out of three patients undergoing RNU a bladder cuff excision was not registered. Conclusions: The population-based SNRUBC with high coverage contributes to the knowledge about UTUC with granular and generalizable data. The present study reveals a high proportion of patients not subjected to curatively intended treatment and suggests unmet needs to shorten lead times to treatment and use of bladder cuff excision when performing radical surgery for UTUC in Sweden.
- Open Access
- 9 November 2023
- Published by Springer Nature in Communications Medicine
- Vol. 3 (1) , 1-8
The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography
Background: Multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) are widely used for the management of prostate cancer (PCa). However, how these modalities complement each other in PCa risk stratification is still largely unknown. We aim to provide insights into the potential of mpMRI and PET for PCa risk stratification. Methods: We analyzed data from 55 consecutive patients with elevated prostate-specific antigen and biopsy-proven PCa enrolled in a prospective study between December 2016 and December 2019. [68Ga]PSMA-11 PET (PSMA-PET), [11C]Acetate PET (Acetate-PET) and mpMRI were co-registered with whole-mount histopathology. Lower- and higher-grade lesions were defined by International Society of Urological Pathology (ISUP) grade groups (IGG). We used PET and mpMRI data to differentiate between grades in two cases: IGG 3 vs. IGG 2 (case 1) and IGG ≥ 3 vs. IGG ≤ 2 (case 2). The performance was evaluated by receiver operating characteristic (ROC) analysis. Results: We find that the maximum standardized uptake value (SUVmax) for PSMA-PET achieves the highest area under the ROC curve (AUC), with AUCs of 0.72 (case 1) and 0.79 (case 2). Combining the volume transfer constant, apparent diffusion coefficient and T2-weighted images (each normalized to non-malignant prostatic tissue) results in AUCs of 0.70 (case 1) and 0.70 (case 2). Adding PSMA-SUVmax increases the AUCs by 0.09 (p < 0.01) and 0.12 (p < 0.01), respectively. Conclusions: By co-registering whole-mount histopathology and in-vivo imaging we show that mpMRI and PET can distinguish between lower- and higher-grade prostate cancer, using partially discriminative cut-off values.
- 9 November 2023
- Published by Springer Nature in Communications Medicine
- Vol. 3 (1) , 1-8
Open AccessThe grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography
Background: Multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) are widely used for the management of prostate cancer (PCa). However, how these modalities complement each other in PCa risk stratification is still largely unknown. We aim to provide insights into the potential of mpMRI and PET for PCa risk stratification. Methods: We analyzed data from 55 consecutive patients with elevated prostate-specific antigen and biopsy-proven PCa enrolled in a prospective study between December 2016 and December 2019. [68Ga]PSMA-11 PET (PSMA-PET), [11C]Acetate PET (Acetate-PET) and mpMRI were co-registered with whole-mount histopathology. Lower- and higher-grade lesions were defined by International Society of Urological Pathology (ISUP) grade groups (IGG). We used PET and mpMRI data to differentiate between grades in two cases: IGG 3 vs. IGG 2 (case 1) and IGG ≥ 3 vs. IGG ≤ 2 (case 2). The performance was evaluated by receiver operating characteristic (ROC) analysis. Results: We find that the maximum standardized uptake value (SUVmax) for PSMA-PET achieves the highest area under the ROC curve (AUC), with AUCs of 0.72 (case 1) and 0.79 (case 2). Combining the volume transfer constant, apparent diffusion coefficient and T2-weighted images (each normalized to non-malignant prostatic tissue) results in AUCs of 0.70 (case 1) and 0.70 (case 2). Adding PSMA-SUVmax increases the AUCs by 0.09 (p < 0.01) and 0.12 (p < 0.01), respectively. Conclusions: By co-registering whole-mount histopathology and in-vivo imaging we show that mpMRI and PET can distinguish between lower- and higher-grade prostate cancer, using partially discriminative cut-off values.
- Open Access
- 17 May 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
- 17 May 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , e438-e448
Open AccessTreatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
- Open Access
- 25 January 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (4) , 868-874
Short term outcomes after robot assisted and open cystectomy - A nation-wide population-based study
- 25 January 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (4) , 868-874
Open AccessShort term outcomes after robot assisted and open cystectomy - A nation-wide population-based study